辉瑞-生物科技（BNT162b2） COVID-19 疫苗加强针接种后对 SARS-CoV-2 奥密克戎变异株的中和能力增强。
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
机构信息
Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
出版信息
Viruses. 2022 Sep 13;14(9):2023. doi: 10.3390/v14092023.
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.
2021 年 11 月下旬，世界卫生组织宣布，SARS-CoV-2 谱系 B.1.1.529 为第五种关切变异株，即奥密克戎。该变异株在刺突蛋白上发生了超过 30 处突变（受体结合域中有 15 处），令人担忧的是，奥密克戎可能逃避自然感染和疫苗诱导的免疫。我们利用真实病毒、多轮中和测定法证明，接种两剂辉瑞-BioNTech BNT162b2 疫苗 1、3 和 6 个月后采集的血清对 SARS-CoV-2 的中和能力有限。然而，第三剂接种四周后，中和抗体滴度升高。尽管有所增加，但与谱系 A.2.2 SARS-CoV-2 相比，奥密克戎的中和抗体滴度降低了四倍。
Zotero 插件